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•	 Prognostic Factors for 
Cure, Recurrence, and 
Long-Term survival After 
surgical Resection of 
Thymoma
three percent of patients had complete resection. Overall 
survival was 95% at 5 years, 91% at 10 years, and 91% 
at 15 years. Twelve patients had recurrence, of which 
three were local mediastinal recurrences. Univariate 
analysis demonstrated that increased Masaoka stage, 
incomplete resection, larger tumor size, and increased 
age were significantly associated with increased 
recurrence (p < 0.0001, p < 0.0009, p < 0.0002, and p 
< 0.04, respectively). Multivariate analysis showed that 
only increased Masaoka stage and tumor size (> 7.0 cm, 
as a continuous predictor) were associated with increased 
recurrence (p < 0.0001 and p < 0.03, respectively). 
Gender, WHO histology, and adjuvant radiotherapy were 
not significant predictors of recurrence. To conclude, 
the findings from this study of 262 cases demonstrated 
incomplete resection, tumor size greater than 7 cm, and 
higher Masaoka stage as adverse prognostic factors. The 
long-term survival data also supported complete surgical 
resection to improve long-term cure. The roles of neo-
adjuvant or adjuvant chemotherapy and/or radiotherapy 
in improving the outcome of stage III and IV tumors 
with recurrence should also be explored. (p. 1018)
This study was a retrospective analysis of a large cohort of thymoma 
patients to evaluate the association between survival and WHO 
histology, tumor size, Masaoka stage, and completeness of resection. 
Thymic resection was performed at Toronto General Hospital (1986–
2010) where radiotherapy has generally been recommended in all 
incomplete resections and stage 2b or greater tumors. Histology of 
many cases (200 of 262) was analyzed by the WHO classification. 
Patients were followed up every 6 months for the first 2 years and 
then annually with computed tomography of the thorax. Eighty 
•	 A high Content 
Clonogenic survival 
Drug screen Identifies 
Mek Inhibitors as Potent 
Radiation sensitizers for 
Kras Mutant non–small-
Cell Lung Cancer
This article described the application of a novel method, 
high content clonogenic survival assay, developed by 
Lin et al. for the identification of potential radiation 
sensitizers from screening drug libraries. Cells in 96-well 
plates were subject to drug treatment, irradiation, and 
incubation, followed by colony staining with crystal 
violet, imaging, and analysis on the INCell 6000 (GE 
Health). H460 lung cancer cell line (KRAS mutant) and 
a Custom Clinical Collection (146 compounds) were 
used in a proof-of-principle screen. The findings revealed 
that a few drugs of the same class sensitized cells to 
radiation with clinically relevant potency. Enhanced 
effects of radiation in H460 cells were observed 
with inhibitors of PI3K, AKT, mTOR, and MEK1/2 
downstream of KRAS, particularly there were synergistic 
effects of tramenitib (MEK1/2 inhibitor) in KRAS 
mutant but not wild-type lung cancer cells. The authors 
concluded that high content clonogenic survival assay 
facilitates drug screening for novel radiation sensitizers, 
which would in turn speed up their discovery and 
development into clinical studies. (p. 965)
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involving asymptomatic adults were included in the 
analysis of the effect of LDCT screening on patient-
centered outcomes, whereas RCTs and cohort studies 
were included for the analysis of association of 
subsequent results and/or recommendations from LDCT 
screening with patient-centered outcomes. Of the 8215 
abstracts reviewed, five publications from two European 
RCTs and one publication from a US cohort study 
were included in this analysis. The findings revealed 
an association between the process of LDCT screening 
and short-term psychologic discomfort, whereas over 
the long term, no significant impact was observed with 
distress, worry, or overall health-related quality of life. 
In the short term, negative results were linked to decline 
in distress whereas false positive results were linked to 
elevated distress, which reversed to levels similar to that 
in negative results. Taken together, this study suggested 
possible short-term distress as a result of false positive 
results from LDCT screening should be taken into 
consideration when individuals are going through the 
procedure, possibly through effective communications 
with clinicians to reduce the distress. (p. 927)
•	 Patient-Centered 
Outcomes among 
Lung Cancer screening 
Recipients with Computed 
Tomography: A systematic 
Review 
The authors reviewed data obtained from the Cochrane Central 
Registry of Controlled Trials and Cochrane Database of Systematic 
Reviews, MEDLINE, reference lists of papers, and Scopus to 
determine the impact of low-dose computed tomography (LDCT) 
screening and subsequent results on patients’ quality of life, 
distress, and anxiety. Only randomized controlled trials (RCT) 
ReseARCh WATCh
•	 epidermal Growth 
Factor Receptor Tyrosine 
Kinase Inhibitors 
 versus Conventional 
Chemotherapy in non–
small-Cell Lung Cancer 
harboring Wild-Type 
epidermal Growth Factor 
Receptor: A Meta-Analysis
database, and meeting abstracts of the American Society 
of Clinical Oncology and European Society of Medical 
Oncology, 11 trials involving 1605 patients with WT 
EGFR were included. Progression-free survival (PFS) 
was the primary outcome, whereas objective response 
rate and overall survival (OS) were the secondary 
outcomes. Improved PFS and objective response rate 
were observed in the chemotherapy arm versus the TKI 
arm (hazard ratio for TKI 1.41; 16.8% versus 7.2%), 
regardless of line of treatment, experimental drug, 
dominant ethnicity, or EGFR mutation analysis method. 
However, there was no statistically significant difference 
in OS between the arms (hazard ratio for TKI, 1.08). 
The authors concluded that conventional chemotherapy 
was associated with improved PFS but not OS, when 
compared with first generation EGFR TKI in advanced 
non–small-cell lung cancer patients with WT EGFR. 
Lee J, Hahn S, Kim D, et al. Epidermal growth factor 
receptor tyrosine kinase inhibitors vs conventional 
chemotherapy in non–small cell lung cancer harboring 
wild-type epidermal growth factor receptor: A meta-
analysis. JAMA 2014;311:1430–1437.
In a meta-analysis conducted by Lee et al., eligible randomized 
controlled trials were reviewed to determine the association of 
first generation epidermal growth factor receptor (EGFR) tyrosine 
kinase inhibitors (TKIs) and chemotherapy with survival in 
advanced non–small-cell lung cancer patients harboring wild-type 
(WT) EGFR. Of 1947 articles from PubMed, EMBASE, Cochrane 
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•	 A Randomized, 
Multicenter, Placebo-
Controlled Clinical 
Trial Of Racotumomab-
Alum Vaccine as switch 
Maintenance Therapy In 
Advanced non–small-Cell-
Lung Cancer Patients 
This clinical study investigated the efficacy and safety of 
racotumomab, a vaccine that targets the NeuGcGM3 tumor-
associated ganglioside, as switch maintenance for stage III/IV non–
small-cell lung cancer patients with prior first-line chemotherapy. 
The primary endpoint was overall survival (OS). The 176 patients 
randomized to racotumomab-alum and placebo (1:1) achieved a 
median OS of 8.23 and 6.80 months, respectively (hazard ratio 
0.63; p = 0.004). The vaccinated group also had improved median 
progression-free survival (5.33 months) versus placebo 
(3.90 months;hazard ratio 0.73; p = 0.039). Adverse 
events such as burning and pain at the injection site, 
bone pain, and asthenia were most common in the 
vaccinated group. Results also showed a high antibody 
response against the NeuGcGM3 ganglioside and its 
specificity in killing ≥30% NeuGcGM3-expressing 
L1210 cell line. Patients who developed the antibodies 
had prolonged median survival. The authors concluded 
that racotumomab-alum as switch maintenance is 
effective and well-tolerated for advanced non–small-
cell lung cancer patients. However, the sample size is 
very small and a larger confirmatory study has to be 
performed.
Alfonso S, Valdes-Zayas A, Santiesteban ER, et 
al. A randomized, multicenter, placebo-controlled 
clinical trial of racotumomab-alum vaccine as 
switch maintenance therapy in advanced non-small-
cell-lung cancer patients. Clin Cancer Res, 2014. 
doi:10.1158/1078-0432.ccr-13-1674.
•	 FGFR1 mRnA and Protein 
expression, not Gene 
Copy number, Predict 
FGFR TKI sensitivity 
Across All Lung Cancer 
histologies 
values less than 50 nM demonstrated an association 
with FGFR1 mRNA and protein expression and mRNA 
expression of the ligands FGF2 and FGF9, but not 
with FGFR1 GCN or histology. High FGFR1 mRNA 
expression was found in 22% of adenocarcinomas and 
28% of SCCs of the resected tumors, but only less than 
half of SCCs with high FGFR1 GCN showed high 
mRNA levels. The findings were validated with TCGA 
lung cancer data and also uncovered the overlapping 
FGFR1 mRNA expression with KRAS and PIK3CA 
mutations. To conclude, this study indicates that FGFR1 
mRNA could be a better biomarker of FGFR TKI 
sensitivity in lung cancer of various histologies when 
compared with FGFR1 GCN. 
Wynes MW, Hinz TK, Gao D, et al. FGFR1 mRNA 
and protein expression, not gene copy number, predict 
FGFR TKI sensitivity across all lung cancer histologies. 
Clin Cancer Res, 2014. doi:10.1158/1078-0432.
ccr-13-3060.
Wynes et al. evaluated the use of FGFR1 mRNA and protein 
expression as better biomarkers of FGFR tyrosine kinase inhibitor 
(TKI) sensitivity in lung cancer in comparison with the use of 
FGFR1 gene copy number (GCN), which assumes that only 
increased GCN is involved in increased FGFR1 signaling. The 
sensitivity to ponatinib, a potent FGFR TKI, was assessed in a range 
of histologically different lung cancer cell lines. FGFR1 GCN and 
mRNA analysis were performed on a tissue microarray of resected 
lung tumors. Ponatinib sensitive cell lines (14 of 58) with IC50 
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•	 Rapidly Increasing 
Promotional expenditures 
For e-Cigarettes
This Industry Watch by Kronfield et al. was aimed to analyze and 
track expenditures in marketing e-cigarettes. Data were obtained from 
Kantar Media, where information on US advertising across media 
platforms (television, print, radio, and the internet) and expenditure 
estimates from market rate (starting from 2008) were available. 
Keywords used in the search of data included generic terms for 
e-cigarettes and component parts, slang terms, and brand names. The 
findings revealed 132 unique brands, mostly e-cigarette brands, with 
advertising expenditures from the beginning of 2008 to mid-2013. 
Promotional spending has risen dramatically since mid-2010 to 
US$12 million in 2011 and US$22 million in 2012. Expenditures 
in the second quarter of 2013 (US$28 million) was eightfold higher 
than that in the same time of 2012. Many of 2013 expenditures were 
in print media, followed by television; more than 60% 
of these expenditures were for a brand called Blu. Taken 
together, this study showed a continued rapid rising 
trend in e-cigarette promotional spending and projected 
a further rise in television advertising along with a rise 
in the market share by tobacco companies. The actual 
extent of e-cigarette promotional spending could be 
underestimated in this study where internet promotion 
including social media and sponsored events were not 
covered. The authors emphasized the need for continued 
monitoring of e-cigarette marketing spending, and 
further studies on the content of e-cigarette promotional 
messages across media channels to guide product 
regulation and policy and to evaluate the claims made in 
the messages and their impact on consumers. 
Kornfield R, Huang J, Vera L, Emery SL. 
Rapidly increasing promotional expenditures for 
e-cigarettes. Tobacco control, 2014. doi:10.1136/
tobaccocontrol-2014-051580.
•	 stimulation of soluble 
Guanylate Cyclase 
Prevents Cigarette  
smoke-Induced Pulmonary 
hypertension and 
emphysema
sGC β1-subunit in COPD patients and CS-exposed 
mice. Treatment with sGC stimulators suppressed the 
development of PH and emphysema in CS-exposed 
mice and guinea pigs. The treatment also inhibited 
peroxynitrite-induced apoptosis of alveolar and 
endothelial cells, reduced CS-induced inflammatory cell 
infiltrate in lung parenchyma, and inhibited adhesion 
of CS-stimulated neutrophils. This study indicates 
that the sGC-cGMP pathway is disrupted in chronic 
CS exposure, and stimulation of this pathway could 
be a promising treatment for COPD that will inhibit 
CS-induced PH and emphysema. 
Weissmann N, Lobo B, Pichl A, et al. Stimulation 
of soluble guanylate cyclase prevents cigarette smoke-
induced pulmonary hypertension and emphysema. 
Am J Respir Crit Care Med, 2014. doi:10.1164/
rccm.201311-2037OC.
Weissmann et al. sought to determine the role of the soluble 
guanylate cyclase (sGC)-cGMP pathway in the pathogenesis of 
lung emphysema and pulmonary hypertension (PH), as well as its 
potential in therapeutic intervention for these diseases. A series 
of molecular techniques and functional tests were performed in 
lung tissues of healthy individuals and COPD patients, in mice 
and guinea pigs. Mice and guinea pigs were exposed to cigarette 
smoke (CS) for a period of time, followed by treatment with 
sGC stimulators. The results demonstrated a reduced level of 
neWs-In-BRIeF
•	 FDA Approves Ceritinib for 
Metastatic Lung Cancer
Ceritinib (Zykadia) has been granted accelerated approval 
by the FDA for the treatment of patients with metastatic 
ALK-positive non–small-cell lung cancer (NSCLC) 
with prior crizotinib treatment. This approval came 4 
months ahead of review completion. Zykadia, an ALK 
tyrosine kinase inhibitor, has shown promising results in 
the clinical trial of 163 ALK-positive metastatic NSCLC 
patients, in which about half of the patients had tumor 
shrinkage that lasted an average of about 7 months. 
Common adverse events were diarrhea, abdominal pain, 
nausea, and vomiting. Increased liver enzymes, pancreatic 
enzymes, and increased glucose levels were also reported. 
Photo source: CDC
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•	 Revolutionary Clinical  
Trial to Individualize  
Lung Cancer Treatment 
Photo source: NIH
Partnership between Cancer Research UK, AstraZeneca, 
Pfizer, and the National Health Service (NHS) has 
resulted in the opening of the “National Lung Matrix” 
trial later this year at centers across the United Kingdom 
toward personalized treatments for patients with advanced 
lung cancer. Researchers would have unprecedented 
access to drug libraries of AstraZeneca and Pfizer and are 
able to evaluate up to 14 medicines within one trial. With 
the availability of the genetic profiles of each lung tumor, 
researchers could stratify patients for optimal treatment 
outcomes. Promising drugs might be accelerated into 
larger trials in patients matching the same genetic 
profiles. New drugs could also be added to the existing 
trial when novel experimental treatments are available 
from the laboratory. This trial is led by chief investigator 
Gary Middleton in conjunction with the Early Drug 
Development Team at the Cancer Research UK Clinical 
Trials Unit in Birmingham and will contribute to the 
first phase of Cancer Research UK Stratified Medicine 
Program. This will also allow routine testing of patient 
tumor samples in NHS hospitals to match patients to the 
best treatment possible. 
•	 AATs Annual Meeting 
2014: Breath Analysis 
Offers noninvasive 
Method to Detect early 
Lung Cancer
Previous study identified carbonyl compounds found 
in the breath as elevated cancer markers, which could 
distinguish patients with benign lung disease from those 
with lung cancer. In this study, researchers sought to 
compare the sensitivity and specificity of a noninvasive 
tool, coated with silicon microchips for breath analysis, 
with PET scans in lung cancer detection. Michael 
Bousamra II presented the preliminary data at the 94th 
American Association for Thoracic Surgery annual 
meeting. From a group of 88 healthy controls, 107 lung 
cancer patients, 40 individuals with benign pulmonary 
disease, and seven with metastatic lung cancer, the 
investigators found that the sensitivity and specificity 
of breath analysis was dependent on the number 
of elevated cancer markers: 0 or 1 in most benign 
pulmonary disease; 3 or 4 in stage IV cancer. When 
used to differentiate early-stage lung cancer from benign 
disease, breath analysis, and PET scanning showed 
similar sensitivities (82.8% and 90.3%, respectively). But 
a much higher specificity was found in breath analysis 
versus PET scanning to distinguish benign disease (75% 
versus 38.7%, respectively), indicating higher accuracy 
in breath analysis to identify individuals without cancer 
and hence avoiding unnecessary invasive procedure. 
The findings suggested that this noninvasive breath 
analysis offers a cheaper and more reliable diagnosis for 
those without significant disease and rapid and accurate 
diagnosis in conjunction with a positive CT scan result 
for those with lung cancer to expedite treatment.
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•	 Lung Cancer screening in 
smokers
Medpage Today (www.medpagetoday.com) reported 
on May 1 the rejection of low-dose CT screening for 
lung cancer by a Medicare Advisory Panel. The article 
reports on the surprise and disappointment of the 
presenting medical professionals in light of the results 
of the National Lung Screening Trial. The panel is not 
because of make final this decision until 2015 but, it is 
reported, no other highly powered trials are expected to 
be complete by then.
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across television, print media, and online. According 
to the NBC report, not only is the use of e-cigarettes 
rising among young people, a major e-cigarette brand, 
Blu, is owned by a major tobacco company Lorillard 
which, according to a Bloomberg Business week report, 
attributes 4% of its revenue from e-cigarettes. In light 
of all this, restrictions on e-cigarettes are developing in 
New York State (from the New York Post) and Chicago 
(Chicago Tribune) as the FDA considers regulation 
of e-cigarettes. A proposed rule by the FDA (open for 
comment until the 7th of July 2014) seeks to extend the 
definition of “tobacco product” over which the FDA has 
regulatory authority to include new categories, including 
e-cigarettes; CNN reports a proposed age limit of 18 
for purchase of e-cigarettes once the rule becomes 
final (http://edition.cnn.com/2014/04/24/health/fda-e-
cigarette-regulations/). You can read the rule on the FDA 
website (link below).
http://www.nbcnews.com/health/kids-health/e-cigarette-
makers-going-after-youth-report-finds-n94166.
http://legacyforhealth.org/content/
download/4542/63436/version/1/file/LEG-
Vaporized-E-cig_Report-May2014.pdf.
http://www.businessweek.com/articles/2013-10-23/
blu-e-cigarettes-help-lorillard-capture-half-the-u-dot-
s-dot-market.
http://nypost.com/2014/04/29/albany-moves-to-ban-e-
cigs-in-public-after-citys-ban/.
http://www.chicagotribune.com/news/local/ct-e-
cigarette-indoor-ban-met-20140430,0,565726.story.
https://www.federalregister.gov/articles/2014/04/25/ 
2014-09491/deeming-tobacco-products-to-be-
subject-to-the-federal-food-drug-and-cosmetic-act-
as-amended-by-the.
•	 e-Cigarettes
Photo source: FDA
This has been a big month for e-cigarette literature and news. In 
Australia, the Sydney Morning Herald reported on April 27 the 
banning of the sale of electronic cigarettes in Western Australia. The 
paper reports that the ban follows a WA Health Department appeal 
over a magistrate decision that there was insufficient evidence to 
suggest that e-cigarettes resembled tobacco cigarettes.
http://www.smh.com.au/national/health/electronic-cigarettes-
the-truth-behind-the-smoke-and-mirrors-20140426-37aum.html . 
The appeal was successful; the Western Australian Supreme Court 
decision (April 10), among other things, concluded that e-cigarettes 
were “designed to resemble a tobacco product” referring 
“particularly [to] the conveyance of the electronic cigarette to the 
user’s mouth using their hand, the inhalation and exhalation of the 
vapor, and the fact that the vapour is reminiscent of the smoke from 
a cigarette”. www.supremecourt.wa.gov.au. NBC News reports on 
a study from Legacy, an American tobacco control not-for-profit 
organization, examining the marketing of e-cigarettes to young 
people, was released on May 1, 2014. The report addresses concerns 
that include dual use of cigarettes and e-cigarettes and therefore 
reduction in quitting, the potential for harm from e-cigarettes, the 
rise of e-cigarette use among young people and marketing strategies 
such as flavored e-cigarettes and high levels of advertising spending 
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•	 Plain Packaging—The Fight 
Continues
The effort to introduce a bill for plain cigarette 
packaging in New Zealand attracted some controversial 
comment in April when the health select committee 
overseeing a briefing decided to show to the media, 
artwork by children in support of the bill. Business 
Day reports that the committee will hold a briefing 
on more than 17,000 submissions on the Smoke-Free 
Environments (Tobacco Plain Packing) Amendment 
Bill, 10,000 of which are thought to have been arranged 
in a campaign run by New Zealand’s major tobacco 
companies. The bill is expected to pass but the NZ 
Government has indicated that it would wait for a WTO 
challenge to Australia’s plain packaging legislation 
before proceeding further.
http://www.stuff.co.nz/business/industries/9939539/
Plain-pack-tobacco-fight-heats-up.
•	 “Tobacco is Murderous” The BBC reports on a meeting between US President 
Barack Obama and the Uruguayan Presdent Jose Mujica 
where they discussed Uruguay’s restrictions on tobacco 
smoking. Uruguay introduced a ban on smoking in 
public places in 2006 and is currently being sued by 
Philip Morris, the global tobacco company. Mr. Mujica 
was quoted in strong language, “eight million people die 
each year [in the work] from smoking tobacco....this is 
mass murder. We are in an arduous fight....against very 
strong [corporate] interests.”
http://www.bbc.com/news/world-latin-america-27383896.
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